Drug interactions
Glimepiride + Vildagliptin
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Overview
Additive glucose-lowering effect increases risk of hypoglycemia when a DPP-4 inhibitor is combined with a sulfonylurea.
Mechanism of action
Pharmacodynamic: Vildagliptin enhances glucose-dependent insulin secretion via incretin effects; glimepiride directly stimulates pancreatic insulin release, producing additive hypoglycemia risk.
Clinical management
Consider lowering the glimepiride dose when starting vildagliptin; increase self-monitoring of blood glucose; educate on hypoglycemia recognition and treatment; adjust therapy if recurrent events occur.
Drug reference
References
- Galvus (vildagliptin) Summary of Product Characteristics — EMA
- Vildagliptin: Drug Information — Lexicomp
Frequently asked questions
Can I take Glimepiride with Vildagliptin?
The interaction is rated: Moderate. Additive glucose-lowering effect increases risk of hypoglycemia when a DPP-4 inhibitor is combined with a sulfonylurea.
How serious is the interaction between Glimepiride and Vildagliptin?
The interaction is rated: Moderate. Evidence level: High.
How is the interaction between Glimepiride and Vildagliptin managed?
Consider lowering the glimepiride dose when starting vildagliptin; increase self-monitoring of blood glucose; educate on hypoglycemia recognition and treatment; adjust therapy if recurrent events occur.
Why do Glimepiride and Vildagliptin interact?
Pharmacodynamic: Vildagliptin enhances glucose-dependent insulin secretion via incretin effects; glimepiride directly stimulates pancreatic insulin release, producing additive hypoglycemia risk.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.